Phase II Clinical Trial Data Establishes Effectiveness of using a Child's Own Cord Blood to Treat Cerebral Palsy

Key Discoveries in the Therapeutic Application of Cord Blood: Improvement of Motor Function in Children with Cerebral Palsy WALTHAM, Mass.–(BUSINESS WIRE)– Research published in Stem Cells Translational Medicine shows encouraging developments related to using a child’s own cord blood to treat childhood brain injury known as cerebral palsy (CP). The research from a Phase II... Read more

Thermo Fisher Scientific Signs Oncology Companion Diagnostic Development Agreement with Blueprint Medicines

Thermo Fisher Scientific Signs Oncology Companion Diagnostic Development Agreement with Blueprint Medicines Agreement to expand Oncomine Dx Target Test with RET fusion markers to treat non-small cell lung cancer patients CARLSBAD, Calif., Oct. 31, 2017 /PRNewswire/ — As part of its ongoing commitment to increase the utility of next-generation sequencing (NGS) in the clinic, Thermo Fisher... Read more

New data suggest Roche’s etrolizumab can provide clinically meaningful improvements in the treatment of two of the most common forms of inflammatory bowel disease

Basel, 31 October 2017 New data suggest Roche’s etrolizumab can provide clinically meaningful improvements in the treatment of two of the most common forms of inflammatory bowel disease Roche presents etrolizumab data in Crohn’s disease and ulcerative colitis at UEGW Data suggest etrolizumab leads to endoscopic improvement associated with early symptomatic remission in Crohn’s disease... Read more

QIAGEN Accelerates Adoption of Molecular Testing for Life Sciences and Molecular Diagnostics Companies with Launch of Custom Solutions Business 

Trusted QIAGEN partners can now increase their speed to market by leveraging the company’s industry expertise, world-class manufacturing and thousands of product formulations Beverly, Mass., October 30, 2017 – QIAGEN today announced the launch of its Custom Solutions business, extending its commitment to providing life sciences and molecular diagnostics companies with the tools and expertise... Read more

New OCREVUS (ocrelizumab) data at ECTRIMS advance clinical understanding of underlying progression in multiple sclerosis

Basel, 27 October 2017 New OCREVUS (ocrelizumab) data at ECTRIMS advance clinical understanding of underlying progression in multiple sclerosis Data show superiority of OCREVUS compared to Rebif (interferon beta-1a) in significantly reducing disability Progression Independent of Relapse Activity (PIRA) in people with relapsing multiple sclerosis (RMS) Data demonstrates first method to automatically detect and characterise... Read more

Release of Crossover Cath Lab System, Trinias unity edition Intervention Support with Real Time Image Processing Technology Covering Wide Range of Clinical Usage from Cardiac to Peripheral Region

Cath lab system is X-ray imaging system which is used under interventional treatment to treat patients with angina or cardiac infarct by using cathether. Intervention, which is less invasive treatment compared to surgery operation, recently attracts more attention, and more rapid development has been seen with downsizing and device qualification, reduction of contrast media, and... Read more

Release of Crossover Cath Lab System, Trinias unity edition Intervention Support with Real Time Image Processing Technology Covering Wide Range of Clinical Usage from Cardiac to Peripheral Region

Cath lab system is X-ray imaging system which is used under interventional treatment to treat patients with angina or cardiac infarct by using cathether. Intervention, which is less invasive treatment compared to surgery operation, recently attracts more attention, and more rapid development has been seen with downsizing and device qualification, reduction of contrast media, and... Read more

Shimadzu Scientific Instruments, Cure Pharmaceutical Corp and CK Sciences Form a Strategic Alliance for R&D of Pharmaceutical Cannabis Products

Columbia, MD (October 25, 2017) — Shimadzu Scientific Instruments, the leading provider of cannabis testing instruments, announces it has signed a Memorandum of Understanding (MOU) with Cure Pharmaceutical Corp and CK Sciences. This collaborative agreement will focus on researching and developing safer pharmaceutical cannabis-based products and moving these products through clinical trials using FDA guidelines.... Read more

BD Breaks Ground on $60 Million Expansion of Nebraska Manufacturing Facility

COLUMBUS, Neb., Oct. 25, 2017 /PRNewswire/ — BD (Becton, Dickinson and Company) (NYSE: BDX), a leading global medical technology company, was joined today by Gov. Pete Ricketts and other state and local leaders to break ground on a $60 million upgrade of its Columbus-East facility. The 69,000 sq. ft. expansion will transform the Columbus-East facility into... Read more